Floatz logo

Tislelizumab

Extranodal Nasal NK/T Cell Lymphoma

Explore 50 assets in Extranodal Nasal NK/T Cell Lymphoma →
Floatz Rating
B61/100
Confidence
Indicative
v0.2
Sponsor
Rong Tao
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT07502768CT.gov
Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma
—Recruiting———
NCT07000617CT.gov
A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma
—Recruiting———
NCT05464433CT.gov
Tislelizumab Combined with Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell Lymphoma
—Active Not Recruiting———
NCT05316246CT.gov
Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma
—Unknown———
NCT05058755CT.gov
Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell Lymphoma
—Completed———
NCT04899414CT.gov
Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma
—Unknown———
NCT04425070CT.gov
A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma
—Terminated———
NCT03493451CT.gov
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Extranodal Nasal NK/T Cell Lymphoma

AssetSponsorPhaseRating
Tislelizumab (this asset)Rong TaoP2B · 61
PegaspargaseCStone PharmaceuticalsP4BBB
DexasoneMingzhi ZhangP4BBB
Cis-Diamminedichloroplatinum IiNational Cancer Centre, SingaporeP4BBB
TucidinostatRuijin HospitalP4BB
EtoposideTarapeutics Science Inc.P4BB
LenalidomideXinhua Hospital, Shanghai Jiao Tong University School of MedicineP4BB
Cyclosporin AFred Hutchinson Cancer CenterP2BB
AsparaginaseNational Cancer Centre, SingaporeP3BB

+42 more in the Extranodal Nasal NK/T Cell Lymphoma cohort

Other indications for Tislelizumab

IndicationSponsorPhaseRating
Non-Small Cell Lung Carcinoma—P4BB · 69
Diffuse Large B-Cell Lymphoma—P3BB · 67
Classic Hodgkin Lymphoma—P3BB · 67

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Tislelizumab in Extranodal Nasal NK/T Cell Lymphoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/tislelizumab-extranodal-nasal-nkt-cell-lymphoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →